GLUE insider trading — Monte Rosa Therapeutics, Inc.
Over the last 90 days, insiders at Monte Rosa Therapeutics, Inc. (GLUE) made 0 open-market purchases worth $0 and 1 open-market sale worth $137, making them net sellers by $137. The largest sale was by Bowen Matthew (Principal Accounting Officer), who sold 13 shares for $137 on Oct 5, 2026.
Updated Oct 16, 2026.
Recent GLUE insider transactions
Every Form 4 filed by Monte Rosa Therapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Bowen Matthew | Principal Accounting Officer | S · Sale | Direct | 13 | $10.56 | $137 | Form 4 |
GLUE insider trading FAQ
Are insiders buying GLUE stock?
Not on the open market. In the last 90 days, Monte Rosa Therapeutics, Inc. insiders made no open-market purchases, and 1 open-market sale totaling $137. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading GLUE?
Recent sellers: Bowen Matthew.
Where does GLUE insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.